Shree Ganesh Bio-Tech Reports Revenue Decline in Q2 FY2026

Shree Ganesh Bio-Tech (India) Limited , a company operating in the biotech sector, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company has shown a decrease in both revenue and profitability compared to the previous year.

Financial Highlights

Particulars (in Rs. lakhs)	Q2 FY2026	Q2 FY2025	H1 FY2026	H1 FY2025
Revenue from Operations	76.74	198.40	215.10	554.01
Total Income	117.76	228.69	297.65	621.16
Profit Before Tax	1.41	32.34	34.11	56.12
Net Profit After Tax	1.41	32.34	34.11	56.12

Key Observations

Revenue Performance

The company's revenue from operations for Q2 FY2026 stood at Rs. 76.74 lakhs, showing a significant decrease of 61.32% compared to Rs. 198.40 lakhs in the same quarter of the previous year. For the half-year, revenue reached Rs. 215.10 lakhs, down 61.17% from Rs. 554.01 lakhs in H1 FY2025.

Profitability

Shree Ganesh Bio-Tech reported a profit before tax of Rs. 1.41 lakhs for Q2 FY2026, a sharp decline of 95.64% from Rs. 32.34 lakhs in Q2 FY2025. For the half-year ended September 30, 2025, profit before tax was Rs. 34.11 lakhs, compared to Rs. 56.12 lakhs in the corresponding period of the previous year, indicating a 39.22% decrease in profitability.

Other Income

The company's other income for Q2 FY2026 increased to Rs. 41.01 lakhs from Rs. 30.29 lakhs in Q2 FY2025, helping to partially offset the decline in operational revenue.

Expenses

The cost of material consumed for H1 FY2026 was Rs. 223.72 lakhs, significantly lower than Rs. 535.74 lakhs in H1 FY2025, aligning with the reduced revenue.

Balance Sheet Position

As of September 30, 2025, the company's total assets stood at Rs. 6,513.75 lakhs, with a strong equity base of Rs. 6,359.70 lakhs.

The Board of Directors approved these financial results at their meeting held on November 8, 2025. The company operates in a single business segment, as stated in the notes to the financial statements.

Shree Ganesh Bio-Tech's performance in the second quarter and first half of FY2026 reflects significant challenges in revenue generation and profitability compared to the previous year. However, the company maintains a stable financial position with a strong equity base. Investors and stakeholders may want to monitor the company's strategies for addressing the revenue decline and improving profitability in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.39%	-2.74%	-4.05%	-22.83%	-32.38%	-87.09%

Shree Ganesh Bio-Tech (India) Limited , a Kolkata-based company, has announced its financial results for the quarter ended June 30, showcasing a significant increase in profitability despite a decline in revenue.

Financial Highlights

The company reported a net profit of Rs. 32.70 lacs for the quarter, marking a substantial 37.5% increase from Rs. 23.78 lacs in the corresponding quarter of the previous year. This growth in profitability comes despite a notable decline in revenue, highlighting the company's improved operational efficiency.

Particulars (in Rs. lacs)	Q1 Current	Q1 Previous	YoY Change
Revenue from Operations	138.36	355.61	-61.1%
Total Income	179.89	392.47	-54.2%
Total Expenses	147.19	368.69	-60.1%
Net Profit	32.70	23.78	+37.5%

Revenue and Expenses

Shree Ganesh Bio-Tech experienced a significant decrease in its revenue from operations, which fell to Rs. 138.36 lacs from Rs. 355.61 lacs year-on-year, representing a 61.1% decline. The total income for the quarter stood at Rs. 179.89 lacs, down from Rs. 392.47 lacs in the same quarter of the previous year.

Despite the revenue decline, the company managed to substantially reduce its total expenses to Rs. 147.19 lacs from Rs. 368.69 lacs in the corresponding quarter. This 60.1% reduction in expenses played a crucial role in boosting the company's profitability.

Profitability and Earnings Per Share

The company's efforts in cost management have resulted in an improved bottom line. The net profit margin for the quarter increased significantly, indicating enhanced operational efficiency.

Earnings per share (EPS) remained steady at Rs. 0.01 for both basic and diluted calculations, consistent with the previous year's quarter.

Board Approval and Audit Review

The unaudited financial results were approved by the Board of Directors in a meeting held on July 25. The Board of Directors approved these unaudited financial results, which were also subject to review.

Company Background

Shree Ganesh Bio-Tech (India) Limited, with its registered office in Kolkata, continues to operate in the biotechnology sector.

Conclusion

While Shree Ganesh Bio-Tech faced significant revenue challenges in the quarter ended June 30, its ability to manage costs effectively led to a notable improvement in profitability. Investors and stakeholders will likely be watching closely to see if the company can maintain this efficiency while working to revitalize its revenue streams in the coming quarters.